Medicamen Organ.

Why is Medicamen Organics Ltd falling/rising?

As of 27-Jun, Medicamen Organics Ltd's stock price is at 23.75, down 5.0%. The decline is due to underperformance relative to its sector, decreasing investor participation, and a bearish long-term trend despite a recent positive return.

As of 27-Jun, Medicamen Organics Ltd's stock price is falling, currently at 23.75, which reflects a decrease of 1.25 or 5.0%. This decline can be attributed to several factors. Firstly, the stock has underperformed its sector today by 4.72%, indicating weaker performance relative to its peers. Additionally, while the stock has shown a positive return of 5.32% over the past week, it has experienced a negative trend over the longer term, with a 1.86% decline over the past month and a significant 49.31% drop over the past year.<BR><BR>Investor participation appears to be declining as well, with delivery volume on June 24 falling by 87.5% compared to the 5-day average. This reduction in trading activity suggests a lack of confidence among investors. Furthermore, although the stock is currently above its 5-day and 20-day moving averages, it remains below its 50-day, 100-day, and 200-day moving averages, indicating a bearish trend in the longer term. Overall, these factors contribute to the current downward movement in Medicamen Organics Ltd's stock price.

Which are the latest news on Medicamen Organ.?

What does Medicamen Organ. do?

Medicamen Organics Ltd is a Micro Cap company in the Pharmaceuticals & Biotechnology industry, incorporated in 1995. It has no recent sales or profit data, with a market cap of INR 24 Cr and a negative return on equity of -9.87%.

Overview:<BR>Medicamen Organics Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Micro Cap company.<BR><BR>History:<BR>The company was incorporated in 1995 under the name 'Panchdeep Pharmaceuticals Limited' and later changed its name to 'Medicamen Organics Limited' on November 14, 1995. There is no recent sales or profit data reported.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: N/A<BR>Most recent Net Profit: N/A<BR>Market-cap value: INR 24 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: N/A<BR>Industry P/E: 34<BR>Dividend Yield: 0.00%<BR>Debt-Equity: 0.40<BR>Return on Equity: -9.87%<BR>Price-to-Book: 0.79<BR><BR>Contact Details:<BR>Address: Not available<BR>Phone: Not available<BR>Email: Not available<BR>Website: Not available

Who are the peers of the Medicamen Organ.?

Medicamen Organ.'s peers include Lasa Supergeneri, Mono Pharmacare, Guj. Terce Labs., Shree Ganesh Bio, Chandra Bhagat, Venmax Drugs, Welcure Drugs, Centuple Global, Medi Caps, and Ishita Drugs. Most peers exhibit below average management risk and growth, with Medicamen Organ. showing a 1-year return of -52.93%, worse than its peers.

Peers: The peers of Medicamen Organ. are Lasa Supergeneri, Mono Pharmacare, Guj. Terce Labs., Shree Ganesh Bio, Chandra Bhagat, Venmax Drugs, Welcure Drugs, Centuple Global, Medi Caps, and Ishita Drugs.<BR><BR>Quality Snapshot: Below Average management risk is observed at Lasa Supergeneri, Medicamen Organ., Mono Pharmacare, Guj. Terce Labs., Shree Ganesh Bio, Chandra Bhagat, Venmax Drugs, Medi Caps, and Ishita Drugs, while Average management risk is found at Welcure Drugs. Growth is rated as Good for Mono Pharmacare and Average for Venmax Drugs, while the rest have Below Average growth. Capital Structure is rated as Good at Shree Ganesh Bio, Welcure Drugs, and Medi Caps, Average at Lasa Supergeneri, and Below Average at Medicamen Organ., Mono Pharmacare, Guj. Terce Labs., Chandra Bhagat, Venmax Drugs, and Ishita Drugs.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Guj. Terce Labs. at 0.00%, while the peer with the lowest is Lasa Supergeneri at -44.65%, with Medicamen Organ.'s own 1-year return at -52.93%, indicating it performs worse than both. Additionally, Mono Pharmacare, Guj. Terce Labs., Shree Ganesh Bio, Chandra Bhagat, Venmax Drugs, Welcure Drugs, Centuple Global, Medi Caps, and Ishita Drugs all have a 6-month return of 0.00%.

Is Medicamen Organ. overvalued or undervalued?

As of December 3, 2025, Medicamen Organ. is considered undervalued with a PE ratio of 9.64 and attractive valuation metrics compared to peers like Sun Pharma and Divi's Lab, making it a compelling investment opportunity despite a challenging year.

As of 3 December 2025, Medicamen Organ. has moved from a fair to an attractive valuation grade, indicating a shift in its market perception. The company is currently considered undervalued, with a PE ratio of 9.64, an EV to EBIT of 9.14, and an EV to EBITDA of 7.92, which are significantly lower than its peers. For instance, Sun Pharma. has a PE ratio of 37.51 and an EV to EBITDA of 24.8, while Divi's Lab. shows a PE of 68.92 and an EV to EBITDA of 51.79, highlighting the relative attractiveness of Medicamen's valuation.<BR><BR>In comparison to its peers, Medicamen Organ. stands out with a PEG ratio of 0.00, suggesting that it is priced favorably relative to its growth prospects. Other attractive peers include Cipla and Dr. Reddy's Labs, with PE ratios of 22.39 and 18.52, respectively. Despite a challenging year with a YTD return of -50%, the valuation metrics suggest that Medicamen Organ. presents a compelling investment opportunity in the pharmaceuticals and biotechnology sector.

How has been the historical performance of Medicamen Organ.?

Medicamen Organ experienced significant financial growth from March 2024 to March 2025, with net sales rising to 38.19 Cr and profit after tax increasing to 4.05 Cr. Key metrics such as operating profit and earnings per share also improved, indicating strong overall performance.

Answer:<BR>The historical performance of Medicamen Organ shows significant growth in various financial metrics from March 2024 to March 2025.<BR><BR>Breakdown:<BR>Medicamen Organ's net sales increased from 25.27 Cr in March 2024 to 38.19 Cr in March 2025, contributing to a total operating income rise to 38.19 Cr from 25.27 Cr. The company's total expenditure also grew, reaching 31.60 Cr from 20.53 Cr, primarily driven by higher raw material costs, which rose to 22.25 Cr from 14.40 Cr. Operating profit (PBDIT) improved to 6.69 Cr from 5.81 Cr, although the operating profit margin decreased slightly to 17.26% from 18.76%. Profit before tax increased to 5.43 Cr from 4.44 Cr, leading to a profit after tax of 4.05 Cr, up from 2.62 Cr. The company's earnings per share rose to 3.46 from 3.05, while the book value per share increased to 25.11 from 17.74. On the balance sheet, total assets grew to 59.21 Cr from 38.44 Cr, with total liabilities also increasing to 59.21 Cr from 38.44 Cr. Cash flow from financing activities saw a notable increase to 10.00 Cr from 4.00 Cr, resulting in a net cash inflow of 3.00 Cr compared to no inflow in the previous year. Overall, Medicamen Organ demonstrated a strong financial performance with growth across key metrics.

How big is Medicamen Organ.?

As of 24th July, Medicamen Organics Ltd has a market capitalization of 46.00 Cr, classifying it as a Micro Cap company. Shareholder's Funds are valued at 15.18 Cr, and Total Assets amount to 38.58 Cr, but recent quarterly performance data is unavailable.

As of 24th July, Medicamen Organics Ltd has a market capitalization of 46.00 Cr, which classifies it as a Micro Cap company.<BR><BR>Recent quarterly performance data is not available, so there are no figures for Net Sales or Net Profit for the latest four quarters.<BR><BR>In the balance sheet snapshot for the reporting period of March 2024, Shareholder's Funds are valued at 15.18 Cr, and Total Assets amount to 38.58 Cr.

What is the technical trend for Medicamen?

As of June 3, 2025, Medicamen's technical trend is mildly bullish, supported by the weekly MACD, Bollinger Bands, and Dow Theory, despite some caution from daily moving averages and a bearish weekly KST.

As of 3 June 2025, the technical trend for Medicamen has changed from sideways to mildly bullish. The weekly MACD indicates a mildly bullish stance, while the Bollinger Bands also reflect a bullish condition. The Dow Theory supports this with a mildly bullish signal on both weekly and monthly time frames. However, the daily moving averages are mildly bearish, which introduces some caution. The weekly KST is bearish, but the OBV shows a mildly bullish trend. Overall, the current technical stance is mildly bullish, driven primarily by the weekly MACD, Bollinger Bands, and Dow Theory indicators.

Who are the top shareholders of the Medicamen?

The top shareholders of Medicamen include Bal Kishan Gupta with 52.16%, followed by public shareholder Shivani Chopra at 5.13%. Individual investors collectively hold 28.79%, and there is one Foreign Institutional Investor with a 0.07% stake.

The top shareholders of Medicamen include the promoters, with Bal Kishan Gupta holding the highest share at 52.16%. There are no pledged promoter holdings, and the company has one Foreign Institutional Investor (FII) holding 0.07%. The highest public shareholder is Shivani Chopra, who owns 5.13%. Additionally, individual investors collectively hold 28.79% of the shares.

When is the next results date for Medicamen?

No Upcoming Board Meetings

Has Medicamen declared dividend?

No Dividend History Available